

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE  
DRUG UTILIZATION REVIEW BOARD  
PUBLIC HEARING  
May 31, 2016**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 2:00 p.m., on May 31, 2016 at the Philbrook Building - 121 South Fruit Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The DUR meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Kelly Cote at 603-271-9422 by May 17, 2016. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING  
May 31, 2016  
Meeting Agenda**

I. Introductions and Welcome to Board Members

II. Old Business

1. Minutes – 05/12/15 review

III. New Business

1. NH Medicaid Fee-For-Service Point of Sale Edits (informational only)
  - Morphine equivalent dose for controlled substance medications
2. DUR Business Operations
  - A. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for-Service Program
    - Prospective DUR Reports
    - Utilization Reports
    - Retrospective DUR Reports
  - B. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
    - Antiobesity
    - Bowel disorder
    - CNS Stimulants & ADHD/ADD Medications
    - Hematopoietic Agents
    - Hepatitis C
    - Hyaluronic Acid
    - Oxycontin® (name change to Long Acting Narcotic Analgesics)
    - Suboxone®/buprenorphine
    - Synagis®
    - Systemic Immunomodulators
    - Xolair® (name change to Asthma/Allergy Immunomodulators)
  - C. Proposal of New Clinical Prior Authorization Criteria
    - Methadone
    - Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Medications
  - D. Review of Current Preferred Drug List Therapeutic Classes with Proposed Changes
    - Hepatitis C

#### IV. Adjourn

Further information regarding the agenda items may be obtained after May 17, 2016. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Kelly Cote, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 9422 (in state only), (603) 271-9422, or e-mail at: [kmcote@dhhs.state.nh.us](mailto:kmcote@dhhs.state.nh.us).